PharmiWeb.com - Global Pharma News & Resources

Company Directory

PharmiWeb's Pharma Company Directory is a comprehensive and searchable listing of organisations within the Pharma, Biotech & Life Sciences sector. Use it to find partner organisations, suppliers, or even a company to work for!

As an organisation, a basic listing is FREE, and can raise your profile in the industry, making you visible to thousands of monthly site visitors.

To add your organisation to the directory, simply register as a contributor and add your organisation's details. You can also upgrade to a premium listing for only £500/year, this offers even greater scope for added content (more photos, more links, more copy), and even more exposure.

Note that we only accept contributions relating to the Pharma industry and that it will typically take 2 working days to approve (or otherwise) your details. Once approved, you will also be able to contribute press releases and event details to our site.

Create a free account to list your company for free!

Ad Idem Consulting is a privately-owned, independent recruitment consultancy delivering permanent, interim and contract positions for Finance, Risk & Operations as well as Project Management professionals to businesses of all sizes.
Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer. Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients.
Adamas is a fully integrated pharmaceutical company experienced in drug discovery, development, and delivery of treatments for neurological diseases. We are driven by a deep sense of purpose – to make everyday life significantly better for people affected by neurological disorders.
We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.